ARWR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.50%

Insider Buying (Last 12 Months): $54,990.00

Insider Selling (Last 12 Months): $7,591,494.05

Arrowhead Pharmaceuticals Insider Trading History Chart

Arrowhead Pharmaceuticals Share Price & Price History

^$18.54

▲ +0.26 (1.42%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Arrowhead Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2024	Tracie Oliver	Insider	Sell	9,394	$25.28	$237,480.32	127,107
5/2/2024	Victoria Vakiener	Director	Sell	1,799	$23.31	$41,934.69	30,205
3/20/2024	Hongbo Lu	Director	Buy	1,000	$27.50	$27,500.00	33,680
3/18/2024	Hongbo Lu	Director	Buy	1,000	$27.49	$27,490.00	31,680
3/6/2024	Kenneth Allen Myszkowski	CFO	Sell	40,000	$35.19	$1,407,600.00	400,600
1/31/2024	Christopher Richard Anzalone	CEO	Sell	57,499	$32.35	$1,860,092.65	3,715,048
1/12/2024	James C. Hamilton	Insider	Sell	7,940	$36.89	$292,906.60	210,851
1/11/2024	Douglas B Given	Director	Sell	2,911	$38.06	$110,792.66	129,711
1/5/2024	James C. Hamilton	Insider	Sell	32,143	$35.18	$1,130,790.74	218,791
1/5/2024	Kenneth Allen Myszkowski	CFO	Sell	16,104	$35.27	$567,988.08	440,600
1/5/2024	Patrick C. O'Brien	COO	Sell	22,841	$35.27	$805,602.07	464,385
1/3/2024	James C. Hamilton	Insider	Sell	6,300	$32.19	$202,797.00	175,934
1/3/2024	Patrick C. O'Brien	COO	Sell	8,749	$32.28	$282,417.72	403,826
1/2/2024	Christopher Richard Anzalone	CEO	Sell	9,952	$31.01	$308,611.52	3,715,048
12/20/2023	Christopher Richard Anzalone	CEO	Sell	12,000	$28.54	$342,480.00	3,725,000
11/20/2023	Javier San Martin	Insider	Sell	19,700	$28.80	$567,360.00	131,800
10/25/2023	Christopher Richard Anzalone	CEO	Sell	24,338	$24.21	$589,222.98	3,737,000
9/28/2023	Victoria Vakiener	Director	Sell	1,550	$26.33	$40,811.50	21,734
9/18/2023	Christopher Richard Anzalone	CEO	Sell	57,755	$28.12	$1,624,070.60	3,761,338
7/3/2023	Tracie Oliver	Insider	Sell	8,925	$35.31	$315,141.75	61,575
6/30/2023	James C. Hamilton	Insider	Sell	3,000	$35.53	$106,590.00	188,484
6/27/2023	Kenneth Allen Myszkowski	CFO	Sell	15,000	$36.20	$543,000.00	381,704
5/5/2023	Douglas B Given	Director	Sell	6,500	$40.90	$265,850.00	117,635
5/3/2023	Christopher Richard Anzalone	CEO	Sell	54,928	$39.14	$2,149,881.92	3,761,338
3/3/2023	Adeoye Y. Olukotun	Director	Sell	11,350	$32.65	$370,577.50	7,867
2/27/2023	Douglas B Given	Director	Sell	875	$32.62	$28,542.50	13,000
1/9/2023	William D. Waddill	Director	Sell	3,200	$30.00	$96,000.00	28,950
1/5/2023	James C. Hamilton	Insider	Sell	13,803	$37.40	$516,232.20	191,484
1/5/2023	Patrick C. O'Brien	COO	Sell	15,000	$37.39	$560,850.00	413,375
1/3/2023	James C. Hamilton	Insider	Sell	10,338	$38.38	$396,772.44	145,287
1/3/2023	Patrick C. O'Brien	COO	Sell	17,500	$38.33	$670,775.00	363,375
12/29/2022	Kenneth Allen Myszkowski	CFO	Sell	30,625	$40.00	$1,225,000.00	336,704
11/21/2022	Javier San Martin	Insider	Sell	19,500	$29.99	$584,805.00	91,500
2/11/2022	Christopher Richard Anzalone	CEO	Sell	146,388	$51.91	$7,599,001.08
1/5/2022	Kenneth Allen Myszkowski	CFO	Sell	40,000	$61.70	$2,468,000.00
1/5/2022	Patrick C. O'Brien	General Counsel	Sell	32,500	$61.72	$2,005,900.00
1/4/2022	James C. Hamilton	SVP	Sell	19,375	$65.49	$1,268,868.75
1/3/2022	William D. Waddill	Director	Sell	4,500	$64.72	$291,240.00
12/28/2021	Douglas B Given	Director	Buy	655	$66.37	$43,472.35
12/15/2021	Christopher Richard Anzalone	CEO	Sell	60,000	$67.56	$4,053,600.00

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

62.61% of Arrowhead Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Arrowhead Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	2,964,119	$57.43M	0.0%	+0.9%	2.384%
11/15/2024	Y Intercept Hong Kong Ltd	17,795	$0.35M	0.0%	N/A	0.014%
11/15/2024	Jane Street Group LLC	463,880	$8.99M	0.0%	-18.0%	0.373%
11/15/2024	Wellington Management Group LLP	61,904	$1.20M	0.0%	+1.5%	0.050%
11/15/2024	State Street Corp	6,354,331	$123.08M	0.0%	+8.8%	5.111%
11/15/2024	Quarry LP	6,500	$0.13M	0.0%	-23.5%	0.005%
11/15/2024	Janus Henderson Group PLC	49,845	$0.97M	0.0%	-12.3%	0.040%
11/15/2024	HighTower Advisors LLC	123,477	$2.40M	0.0%	+11.5%	0.099%
11/15/2024	Erste Asset Management GmbH	47,000	$0.92M	0.0%	N/A	0.038%
11/14/2024	PDT Partners LLC	16,241	$0.32M	0.0%	N/A	0.013%
11/14/2024	Verition Fund Management LLC	76,548	$1.48M	0.0%	+80.7%	0.062%
11/14/2024	Captrust Financial Advisors	15,039	$0.29M	0.0%	N/A	0.012%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	2,154,250	$41.73M	0.0%	-5.9%	1.733%
11/14/2024	Zurcher Kantonalbank Zurich Cantonalbank	30,262	$0.59M	0.0%	+5.3%	0.024%
11/14/2024	MetLife Investment Management LLC	131,029	$2.54M	0.0%	-0.8%	0.105%
11/13/2024	BNP Paribas Financial Markets	55,188	$1.07M	0.0%	+40.1%	0.044%
11/13/2024	Quantbot Technologies LP	7,706	$0.15M	0.0%	N/A	0.006%
11/13/2024	FMR LLC	6,067,569	$117.53M	0.0%	-10.9%	4.881%
11/13/2024	The Manufacturers Life Insurance Company	142,040	$2.75M	0.0%	-4.8%	0.114%
11/13/2024	Fisher Asset Management LLC	122,260	$2.37M	0.0%	+941.0%	0.098%
11/12/2024	Algert Global LLC	36,986	$0.72M	0.0%	-8.6%	0.030%
11/12/2024	Charles Schwab Investment Management Inc.	1,006,935	$19.50M	0.0%	+1.3%	0.810%
11/9/2024	Intech Investment Management LLC	34,045	$0.66M	0.0%	N/A	0.027%
11/8/2024	Ontario Teachers Pension Plan Board	16,690	$0.32M	0.0%	-55.6%	0.013%
11/8/2024	B. Metzler seel. Sohn & Co. Holding AG	18,705	$0.36M	0.0%	N/A	0.015%
11/7/2024	Quest Partners LLC	25,493	$0.49M	0.0%	N/A	0.021%
11/7/2024	Thrivent Financial for Lutherans	29,206	$0.57M	0.0%	-2.7%	0.023%
11/6/2024	Mutual of America Capital Management LLC	67,187	$1.30M	0.0%	-5.5%	0.054%
11/5/2024	Victory Capital Management Inc.	39,251	$0.76M	0.0%	-4.5%	0.032%
11/5/2024	WCM Investment Management LLC	219,962	$4.33M	0.0%	-4.1%	0.177%
11/4/2024	State of New Jersey Common Pension Fund D	80,307	$1.56M	0.0%	-1.2%	0.065%
11/2/2024	Privium Fund Management B.V.	333,356	$6.46M	1.6%	+16.2%	0.268%
10/31/2024	Principal Financial Group Inc.	290,994	$5.64M	0.0%	-31.5%	0.234%
10/30/2024	Amalgamated Bank	54,765	$1.06M	0.0%	-8.8%	0.044%
10/29/2024	Van ECK Associates Corp	1,728	$34K	0.0%	-42.0%	0.001%
10/28/2024	Oak Ridge Investments LLC	35,137	$0.68M	0.1%	-4.0%	0.028%
10/28/2024	US Bancorp DE	40,123	$0.78M	0.0%	-11.1%	0.032%
10/25/2024	China Universal Asset Management Co. Ltd.	23,910	$0.46M	0.1%	+63.9%	0.019%
10/25/2024	abrdn plc	401,146	$7.77M	0.0%	+61.3%	0.323%
10/24/2024	Nisa Investment Advisors LLC	1,840	$36K	0.0%	-23.2%	0.001%
10/24/2024	State of Alaska Department of Revenue	14,417	$0.28M	0.0%	+7.3%	0.012%
10/24/2024	DekaBank Deutsche Girozentrale	37,844	$0.74M	0.0%	+4.4%	0.030%
10/24/2024	Wealth Enhancement Advisory Services LLC	14,498	$0.28M	0.0%	+79.6%	0.012%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	4,496	$88K	0.0%	+21.3%	0.004%
10/23/2024	Louisiana State Employees Retirement System	34,500	$0.67M	0.0%	-1.7%	0.028%
10/23/2024	Values First Advisors Inc.	2,685	$52K	0.0%	N/A	0.002%
10/23/2024	Assenagon Asset Management S.A.	293,083	$5.68M	0.0%	+232.5%	0.236%
10/23/2024	Moody Aldrich Partners LLC	48,961	$0.95M	0.2%	-1.8%	0.039%
10/23/2024	Hennion & Walsh Asset Management Inc.	22,516	$0.44M	0.0%	-9.5%	0.018%
10/22/2024	International Assets Investment Management LLC	74,439	$14.42M	0.0%	N/A	0.060%
10/16/2024	Buffington Mohr McNeal	30,000	$0.58M	0.1%	N/A	0.024%
10/11/2024	Creative Planning	25,409	$0.49M	0.0%	-10.1%	0.020%
10/10/2024	Exchange Traded Concepts LLC	40,292	$0.78M	0.0%	-17.7%	0.032%
10/5/2024	Handelsbanken Fonder AB	35,700	$0.69M	0.0%	+17.0%	0.029%
10/3/2024	SG Americas Securities LLC	35,206	$0.68M	0.0%	+275.8%	0.028%
8/16/2024	Quarry LP	8,500	$0.22M	0.1%	+54.5%	0.007%
8/16/2024	Creative Planning	28,276	$0.74M	0.0%	+9.4%	0.023%
8/16/2024	Algert Global LLC	40,466	$1.05M	0.0%	+104.3%	0.033%
8/15/2024	Scientech Research LLC	7,842	$0.20M	0.0%	-48.5%	0.006%
8/15/2024	The Manufacturers Life Insurance Company	149,156	$3.88M	0.0%	+1.1%	0.120%
8/15/2024	Millennium Management LLC	529,251	$13.76M	0.0%	+61.9%	0.426%
8/15/2024	Deerfield Management Company L.P. Series C	19,461	$0.51M	0.0%	N/A	0.016%
8/15/2024	Affinity Asset Advisors LLC	50,000	$1.30M	0.1%	-58.3%	0.040%
8/14/2024	Squarepoint Ops LLC	383,826	$9.98M	0.0%	N/A	0.309%
8/14/2024	Xponance Inc.	16,465	$0.43M	0.0%	-4.8%	0.013%
8/14/2024	Bank of Montreal Can	43,699	$1.20M	0.0%	+240.5%	0.035%
8/14/2024	Avoro Capital Advisors LLC	8,888,888	$231.02M	3.1%	+3.9%	7.157%
8/14/2024	ProShare Advisors LLC	29,081	$0.76M	0.0%	-18.3%	0.023%
8/14/2024	Profund Advisors LLC	32,003	$0.83M	0.0%	-34.6%	0.026%
8/13/2024	Thrivent Financial for Lutherans	30,009	$0.78M	0.0%	-3.3%	0.024%
8/13/2024	Sei Investments Co.	9,908	$0.26M	0.0%	-8.0%	0.008%
8/13/2024	Pacer Advisors Inc.	19,474	$0.51M	0.0%	-2.4%	0.016%
8/12/2024	Seven Eight Capital LP	34,561	$0.90M	0.1%	-54.1%	0.028%
8/12/2024	Vanguard Personalized Indexing Management LLC	12,751	$0.33M	0.0%	+23.2%	0.010%
8/12/2024	Amalgamated Bank	60,052	$1.56M	0.0%	-7.1%	0.048%
8/12/2024	E Fund Management Co. Ltd.	8,900	$0.23M	0.0%	-31.3%	0.007%
8/10/2024	Mutual of America Capital Management LLC	71,111	$1.85M	0.0%	-3.7%	0.057%
8/9/2024	Edgestream Partners L.P.	53,918	$1.40M	0.1%	N/A	0.043%
8/9/2024	Dimensional Fund Advisors LP	145,874	$3.79M	0.0%	+139.1%	0.117%
8/8/2024	Federated Hermes Inc.	7,201	$0.19M	0.0%	-51.1%	0.006%
8/8/2024	DekaBank Deutsche Girozentrale	36,235	$0.93M	0.0%	-4.3%	0.029%
8/8/2024	Meeder Asset Management Inc.	3,405	$88K	0.0%	+4,629.2%	0.003%
8/8/2024	State of New Jersey Common Pension Fund D	81,323	$2.11M	0.0%	-11.1%	0.065%
8/7/2024	Texas Permanent School Fund Corp	100,304	$2.61M	0.0%	-7.5%	0.081%
8/5/2024	Arizona State Retirement System	34,685	$0.90M	0.0%	+2.4%	0.028%
8/5/2024	Victory Capital Management Inc.	41,090	$1.07M	0.0%	+67.3%	0.033%
8/3/2024	TD Asset Management Inc	54,200	$1.41M	0.0%	+90.8%	0.044%
8/2/2024	Wealth Effects LLC	159,600	$4.15M	1.5%	-3.0%	0.129%
8/1/2024	Rhumbline Advisers	383,029	$9.96M	0.0%	+2.9%	0.308%
8/1/2024	Privium Fund Management B.V.	286,936	$7.24M	1.9%	+4.7%	0.231%
7/31/2024	nVerses Capital LLC	3,700	$96K	0.1%	N/A	0.003%
7/31/2024	Commonwealth Equity Services LLC	34,663	$0.90M	0.0%	+3.7%	0.028%
7/29/2024	Crossmark Global Holdings Inc.	7,828	$0.20M	0.0%	-6.3%	0.006%
7/29/2024	Principal Financial Group Inc.	424,766	$11.04M	0.0%	-12.3%	0.342%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	28,739	$0.75M	0.0%	+20.7%	0.023%
7/26/2024	State of Michigan Retirement System	29,870	$0.78M	0.0%	-2.0%	0.024%
7/26/2024	Bank of New York Mellon Corp	1,085,069	$28.20M	0.0%	+2.9%	0.874%
7/26/2024	EFG Asset Management North America Corp.	51,828	$1.35M	0.2%	+86.8%	0.042%
7/25/2024	Banque Pictet & Cie SA	104,792	$2.72M	0.0%	-3.0%	0.084%
7/24/2024	Retirement Systems of Alabama	153,292	$3.98M	0.0%	-56.0%	0.123%

Data available starting January 2016

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $18.54

$18.13

$18.87

50 Day Range

MA: $19.86

$17.70

$21.97

52 Week Range

Now: $18.54

$17.05

$39.83

Volume

1,036,900 shs

Average Volume

1,196,750 shs

Market Capitalization

$2.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Who are the company insiders with the largest holdings of Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' top insider shareholders include:
Christopher Richard Anzalone (CEO)
Patrick O'brien (COO)
Kenneth Allen Myszkowski (CFO)
James C Hamilton (Insider)
Martin Javier San (Insider)
Douglas B Given (Director)
Tracie Oliver (Insider)
Hongbo Lu (Director)
Victoria Vakiener (Director)
William D Waddill (Director)
Adeoye Y Olukotun (Director)
Learn More about top insider investors at Arrowhead Pharmaceuticals.
Who are the major institutional investors of Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' top institutional shareholders include:
State Street Corp — 5.11%
FMR LLC — 4.88%
Geode Capital Management LLC — 2.38%
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC — 1.73%
Charles Schwab Investment Management Inc. — 0.81%
Jane Street Group LLC — 0.37%
Learn More about top institutional investors of Arrowhead Pharmaceuticals stock.
Which institutional investors are selling Arrowhead Pharmaceuticals stock?: During the last quarter, ARWR stock was sold by these institutional investors:
FMR LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Principal Financial Group Inc.
Jane Street Group LLC
Ontario Teachers Pension Plan Board
WCM Investment Management LLC
Exchange Traded Concepts LLC
The Manufacturers Life Insurance Company
In the last year, company insiders that have sold Arrowhead Pharmaceuticals company stock include:
Christopher Richard Anzalone (CEO)
Patrick O'brien (COO)
Kenneth Allen Myszkowski (CFO)
James C Hamilton (Insider)
Martin Javier San (Insider)
Douglas B Given (Director)
Tracie Oliver (Insider)
Learn More investors selling Arrowhead Pharmaceuticals stock.
Which institutional investors are buying Arrowhead Pharmaceuticals stock?: Within the last quarter, ARWR stock was acquired by institutional investors including:
State Street Corp
Assenagon Asset Management S.A.
abrdn plc
Fisher Asset Management LLC
International Assets Investment Management LLC
Erste Asset Management GmbH
Privium Fund Management B.V.
Verition Fund Management LLC